dc.contributor.author | Heskamp, S | |
dc.contributor.author | Heijmen, L | |
dc.contributor.author | Gerrits, D | |
dc.contributor.author | Molkenboer-Kuenen, JDM | |
dc.contributor.author | Ter Voert, EGW | |
dc.contributor.author | Heinzmann, K | |
dc.contributor.author | Honess, DJ | |
dc.contributor.author | Smith, DM | |
dc.contributor.author | Griffiths, JR | |
dc.contributor.author | Doblas, S | |
dc.contributor.author | Sinkus, R | |
dc.contributor.author | Laverman, P | |
dc.contributor.author | Oyen, WJG | |
dc.contributor.author | Heerschap, A | |
dc.contributor.author | Boerman, OC | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2016-11-14T16:49:27Z | |
dc.date.issued | 2017-08 | |
dc.identifier | http://www.ncbi.nlm.nih.gov/pubmed/27798786 | |
dc.identifier | 10.1007/s11307-016-1021-2 | |
dc.identifier.citation | Mol Imaging Biol, 2017, 19 (4), pp. 540 - 549 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/205 | |
dc.identifier.eissn | 1860-2002 | |
dc.identifier.doi | 10.1007/s11307-016-1021-2 | |
dc.description.abstract | PURPOSE: The aim of the study was to investigate the potential of diffusion-weighted magnetic resonance imaging (DW-MRI) and 3'-dexoy-3'-[(18)F]fluorothymidine ([(18)F]FLT) positron emission tomography (PET) as early biomarkers of treatment response of 5-fluorouracil (5-FU) in a syngeneic rat model of colorectal cancer liver metastases. PROCEDURES: Wag/Rij rats with intrahepatic syngeneic CC531 tumors were treated with 5-FU (15, 30, or 60 mg/kg in weekly intervals). Before treatment and at days 1, 3, 7, and 14 after treatment rats underwent DW-MRI and [(18)F]FLT PET. Tumors were analyzed immunohistochemically for Ki67, TK1, and ENT1 expression. RESULTS: 5-FU inhibited the growth of CC531 tumors in a dose-dependent manner. Immunohistochemical analysis did not show significant changes in Ki67, TK1, and ENT1 expression. However, [(18)F]FLT SUVmean and SUVmax were significantly increased at days 4 and 7 after treatment with 5-FU (60 mg/kg) and returned to baseline at day 14 (SUVmax at days -1, 4, 7, and 14 was 1.1 ± 0.1, 2.3 ± 0.5, 2.3 ± 0.6, and 1.5 ± 0.4, respectively). No changes in [(18)F]FLT uptake were observed in the nontreated animals. Furthermore, the apparent diffusion coefficient (ADCmean) did not change in 5-FU-treated rats compared to untreated rats. CONCLUSION: This study suggests that 5-FU treatment induces a flare in [(18)F]FLT uptake of responsive CC531 tumors in the liver, while the ADCmean did not change significantly. Future studies in larger groups are warranted to further investigate whether [(18)F]FLT PET can discriminate between disease progression and treatment response. | |
dc.format.extent | 540 - 549 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.relation.isreplacedby | internal/739 | |
dc.relation.isreplacedby | https://repository.icr.ac.uk/handle/internal/739 | |
dc.subject | 5-Fluorouracil | |
dc.subject | Colorectal cancer | |
dc.subject | Diffusion-weighted MRI | |
dc.subject | Response monitoring | |
dc.subject | [18F]FLT PET | |
dc.title | Response Monitoring with [(18)F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-10-06 | |
rioxxterms.versionofrecord | 10.1007/s11307-016-1021-2 | |
rioxxterms.licenseref.startdate | 2017-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Mol Imaging Biol | |
pubs.declined | 2016-11-14T16:48:30.558+0000 | |
pubs.deleted | 2016-11-14T16:48:30.558+0000 | |
pubs.issue | 4 | |
pubs.merge-to | internal/739 | |
pubs.merge-to | https://repository.icr.ac.uk/handle/internal/739 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.publication-status | Published | |
pubs.volume | 19 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Translational Molecular Imaging | en_US |
dc.contributor.icrauthor | Oyen, Willem | |